Sintilimab for the treatment of non-small cell lung cancer

Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in first-line treatments. Sintilimab is a domestic anti-PD-1 monoclonal antibody in China that has...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lin, Lin, Weihao, Tan, Fengwei, Li, Ning, Xue, Qi, Gao, Shugeng, Gao, Yibo, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014583/
https://www.ncbi.nlm.nih.gov/pubmed/35436956
http://dx.doi.org/10.1186/s40364-022-00363-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014583/
https://www.ncbi.nlm.nih.gov/pubmed/35436956
http://dx.doi.org/10.1186/s40364-022-00363-7

Ejemplares similares